Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L)
Barbara Becattini1, Shinichi Kitada, Marilisa Leone
1The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
Abstract:
Antiapoptotic Bcl-2-family proteins Bcl-2 and Bcl-X(L) have been recently validated as drug discovery targets for cancer. Here, by using a combination of molecular modeling, NMR-based structural analysis, fluorescence polarization assays, and cell-based assays, we have designed and characterized a novel proapoptotic compound targeting these proteins. Our compound, Apogossypol, is capable of binding and inhibiting Bcl-2 and Bcl-X(L) with high affinity and induces apoptosis of tumor cell lines. Mechanistic studies on the action of our compound were also performed via confocal microscopy that provided real-time detection of the interaction with Bcl-X(L) in intact cells. Finally, preliminary data on cells freshly isolated from patients affected by chronic lymphocytic leukemia strongly suggest potential applications of Bcl-2 antagonists as chemosensitizers in cancer therapy.
Insights
Scientists developed Apogossypol, a novel compound targeting antiapoptotic proteins Bcl-2 and Bcl-X(L). This cancer drug candidate effectively inhibits these proteins, inducing tumor cell death and showing potential as a chemosensitizer in leukemia therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Antiapoptotic proteins Bcl-2 and Bcl-X(L) are validated drug targets in cancer therapy.
- Targeting these proteins offers a promising strategy for cancer treatment.
Purpose of the Study:
- To design and characterize a novel proapoptotic compound targeting Bcl-2 and Bcl-X(L).
- To evaluate the compound's efficacy in inhibiting target proteins and inducing cancer cell apoptosis.
Main Methods:
- Molecular modeling and NMR-based structural analysis.
- Fluorescence polarization and cell-based assays.
- Confocal microscopy for real-time mechanistic studies.
Main Results:
- A novel compound, Apogossypol, was designed and characterized.
- Apogossypol exhibits high-affinity binding and inhibition of Bcl-2 and Bcl-X(L).
- The compound effectively induces apoptosis in tumor cell lines and shows potential in chronic lymphocytic leukemia cells.
Conclusions:
- Apogossypol is a potent inhibitor of Bcl-2 and Bcl-X(L), inducing cancer cell apoptosis.
- Bcl-2 antagonists like Apogossypol hold promise as chemosensitizers in cancer therapy, particularly for leukemia.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
